Site notifications

Sub menu

 

 

Cancellations and suspensions

This database records details of medicines and medical devices that have been cancelled or suspended, and no longer appear in the ARTG.

Following a review by the TGA, complementary medicines can be cancelled from the Australian Register of Therapeutic Goods. These cancellations are made by the Secretary under section 30 of the Therapeutic Goods Act 1989.

Where other actions are taken in relation to safety, a link to the TGA's safety alert will be included in the database under 'Further information'.

The reasons for a cancellation are stated in the database below under 'Grounds for cancellation'.

The heading 'Decision status' provides updated information about cancellation decisions, for example information about any decision to revoke a cancellation decision. It will not appear in every entry.

To find out whether a product is currently authorised for supply in Australia, check the ARTG.

Last updated
Use the filters below to narrow your search.

Filter results

You can narrow down the results using the filters.

Action

Date of effect

Find out more about Cancellations and Suspensions.

Filters applied:Clear all
204 result(s) found, displaying 201 to 204

  • Colocap Balance (Cancelled under Subsection 30 (1A) and 30(2))

    Cancellation or suspension
    Regulatory action due to As the medicine is now required to be included in another part of the Register under ss.10B(1)(a) and ss.10B(7)(b)(i), the medicine has became ineligible for listing s.30(1A)(a) of the Act., effective 23/11/2012

  • BergaMet Mega (Cancelled under s.30(2)(ba) of the Act)

    Cancellation or suspension
    Regulatory action due to As there was insufficient evidence to support the indications for the product and the presentation of the product was unacceptable, the certifications made by the applicant under s.26A(2)(c) and (j) were incorrect., effective 09/10/2012

  • Reducta Fatblaster Tablets (Cancelled under s.30(2)(ba) of the Act)

    Cancellation or suspension
    Regulatory action due to As there was insufficient evidence to support the indications for the product and the presentation of the product was unacceptable, the certifications made by the applicant under s.26A(2)(c) and (j) were incorrect., effective 15/08/2012
Last updated